FFA
NBIX icon

Farther Finance Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Farther Finance Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$488K Buy
3,438
+935
+37% +$150K ﹤0.01% 1618
2026
Q2 		$422K Sell
2,503
-444
-15% -$65.9K ﹤0.01% 1680
2026
Q1 		$391K Buy
2,947
+193
+7% +$25.6K ﹤0.01% 1563
2025
Q4 		$391K Buy
2,754
+1,620
+143% +$235K ﹤0.01% 1476
2025
Q3 		$159K Buy
1,134
+215
+23% +$29.1K ﹤0.01% 1745
2025
Q2 		$116K Buy
919
+233
+34% +$26.7K ﹤0.01% 1688
2025
Q1 		$73.4K Buy
686
+193
+39% +$24.4K ﹤0.01% 1687
2024
Q4 		$67.3K Buy
493
+51
+12% +$6.31K ﹤0.01% 1502
2024
Q3 		$50.9K Hold
442
– – ﹤0.01% 1641
2024
Q2 		$61.9K Buy
442
+7
+2% +$960 ﹤0.01% 1329
2024
Q1 		$61.5K Buy
435
+5
+1% +$683 ﹤0.01% 1110
2023
Q4 		$56.7K Buy
430
+7
+2% +$806 ﹤0.01% 994
2023
Q3 		$47.6K Buy
423
+413
+4,130% +$43.5K 0.01% 789
2023
Q2 		$943 Buy
10
+5
+100% +$489 ﹤0.01% 1994
2023
Q1 		$506 Hold
5
– – ﹤0.01% 2002
2022
Q4 		$597 Buy
+5
New +$586 ﹤0.01% 1799

Other funds holding NBIX

CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return
ACM
Argent Capital Management St Louis, Missouri $3.14B AUM 31.36% 1-Year Est. Return
RSC
Red Spruce Capital Berwyn, Pennsylvania $283M AUM 29.49% 1-Year Est. Return
MNBTD
Moody National Bank Trust Division Galveston, Texas $1.21B AUM 28.25% 1-Year Est. Return
JWS
Juncture Wealth Strategies Scottsdale, Arizona $390M AUM 19.15% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
WWM
Whalen Wealth Management Las Vegas, Nevada $234M AUM 28.06% 1-Year Est. Return
PCS
Private Client Services Louisville, Kentucky $372M AUM 17.65% 1-Year Est. Return
CCAL
City Center Advisors LLC Troy, Michigan $131M AUM 24.02% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 19.15% 1-Year Est. Return

Farther Finance Advisors's NBIX Position: Q3 2026 in Review

Farther Finance Advisors increased its Neurocrine Biosciences (NBIX) stake by 37% in Q3 2026, buying an estimated $150K and bringing the position to 3,438 shares worth $488K. The position accounts for ﹤0.01% of the portfolio, ranked #1618.

Farther Finance Advisors first reported a position in NBIX in Q4 2022 and has held it in 16 quarters since. 21 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

  • Farther Finance Advisors held 3,438 shares of Neurocrine Biosciences worth $488K as of Q3 2026.
  • Farther Finance Advisors bought 935 Neurocrine Biosciences shares in Q3 2026, an estimated $150K.
  • Neurocrine Biosciences made up ﹤0.01% of Farther Finance Advisors's portfolio in Q3 2026, its #1618 holding.
  • Farther Finance Advisors first reported a position in Neurocrine Biosciences in Q4 2022 and has held it in 16 quarters since.
  • 21 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on Farther Finance Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.